# A Prospective, Noninterventional, Observational Study of Late-Onset Pompe Disease

> **NCT02221362** · — · TERMINATED · sponsor: **BioMarin Pharmaceutical** · enrollment: 30 (actual)

## Conditions studied

- Late-onset Pompe Patients Untreated or Treated With rhGAA

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02221362
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221362, "A Prospective, Noninterventional, Observational Study of Late-Onset Pompe Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02221362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*